Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.

Trial Details

NCT ID
NCT05699655
Phase
PHASE2 / PHASE3
Sponsor
Fujian Cancer Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Tislelizumab
  • apatinib
  • oxaliplatin
  • S-1
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

  • Age: 18-70 years of age.
  • Histologically confirmed gastric adenocarcinoma was diagnosed in patients with locally advanced gastric cancer with tumor volume \>5cm Borrmann III…
  • Measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1.
  • ECOG(Eastern Cooperative Oncology Group)PS(Performance Status):0-1 scores.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →